Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy
NCT ID: NCT01590615
Last Updated: 2017-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
54 participants
OBSERVATIONAL
2012-04-26
2017-04-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hepatitis B Patients Under Oral Nucleos(t)Ide Treatment With Intermittent Assessment of Kidney Function
NCT02267473
Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
NCT05718700
Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B
NCT01581554
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
NCT02258581
Assessment and Monitoring of Renal Proximal Tubular Tolerance of Nucleoside and Nucleotide Analogues Using Early Screening Tools in Patients Chronically Mono-infected With Hepatitis B Virus
NCT01500265
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with chronic HBV infection
Participants with decompensated liver disease due to chronic HBV infection, who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy, will be included in the study.
Anti-HBV nucleoside/nucleotide therapy
Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-HBV nucleoside/nucleotide therapy
Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Negative serologies for HIV, hepatitis C virus (HCV), and/or hepatitis D virus (HDV)
* No history of solid organ or bone marrow transplant
* Currently receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy within 6 months of inclusion into registry
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilead Study Director
Role: STUDY_DIRECTOR
Gilead Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cedars-Sinai Medical Center for Liver Diseases and Transplantation
Los Angeles, California, United States
University of California Los Angeles
Los Angeles, California, United States
Stanford University
Palo Alto, California, United States
University of California at San Francisco Medical Center
San Francisco, California, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Georgetown University Hospital
Washington D.C., District of Columbia, United States
Jackson Memorial Hospital
Miami, Florida, United States
Florida Hospital Transplant
Orlando, Florida, United States
Emory University Hospital
Atlanta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Henry Ford Health System
Detroit, Michigan, United States
Saint Louis University Hospital
St Louis, Missouri, United States
Alegent Creighton Health
Omaha, Nebraska, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Oregon Health and Science University
Portland, Oregon, United States
Methodist University Hospital
Memphis, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Baylor All Saints Medical Center
Fort Worth, Texas, United States
The Methodist Hospital
Houston, Texas, United States
Virginia Commonwealth University
Richmond, Virginia, United States
Harborview Medical Center
Seattle, Washington, United States
University of Calgary
Calgary, Alberta, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
Vancouver ID Research and Care Centre Society
Vancouver, British Columbia, Canada
Toronto Liver Centre
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GX-US-174-0172
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.